title: Why could passive Immunoglobulin E antibody therapy be safe in clinical oncology?
authors.forename: E
authors.initials: E
authors.lastname: Jensen-Jarolim
authors.forename: J
authors.initials: J
authors.lastname: Singer
mesh_terms: D000818:Animals; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects*; D001491:Basophils / Q000276:immunology*; D002277:Carcinoma / Q000628:therapy*; D005260:Female; D058975:Folate Receptor 1 / Q000276:immunology*; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000209:etiology*; D010051:Ovarian Neoplasms / Q000628:therapy*; D017455:Receptors, IgE / Q000276:immunology*
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D058975:Folate Receptor 1; C424863:MOv18 monoclonal antibody; D017455:Receptors, IgE